Bill Lundberg

Bill Lundberg

No open positions remaining

Net worth: 17 844 $ as of 2026-08-30

62 year
Health Technology
Consumer Services
Finance

Profile

Sven Ante Lundberg is currently Chairman at Yarrow Bioscience, Inc. since 2026, Director at Q32 Bio Operations, Inc., and Independent Director at Q32 Bio, Inc. since 2024.
Former roles include President, CEO & Executive Director at Merus NV from 2023 to 2025; Independent Director at Vor Biopharma, Inc. from 2019 to 2025; Chief Scientific Officer at CRISPR Therapeutics AG from 2015 to 2018; Vice President & Head-Translational Medicine at Alexion Pharmaceuticals, Inc. from 2011 to 2015; Director & Chief Medical Officer at Taligen Therapeutics, Inc. from 2010 to 2012; Medical Director at Wyeth LLC and Genzyme Corp.; Director at Alliance for Regenerative Medicine; Principal at Antisoma Research Ltd. and Antisoma, Inc.; Vice President-Clinical Development at Sarossa Capital Ltd. Education includes undergraduate studies at Massachusetts Institute of Technology, MBA degrees from the University of Massachusetts and The Isenberg School of Management, and a doctorate from Stanford University School of Medicine.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
0%
2026-06-11 1,200 ( 0% ) 17 844 $ 2026-08-30

Bill Lundberg active positions

CompaniesPositionStart
Director/Board Member -

Former positions of Bill Lundberg

CompaniesPositionEnd
MERUS N.V. Chief Executive Officer 2025-12-11
VOR BIOPHARMA INC. Director/Board Member 2025-07-16
CRISPR THERAPEUTICS AG Chief Tech/Sci/R&D Officer 2018-02-07
ALEXION PHARMACEUTICALS, INC. Corporate Officer/Principal 2015-01-31
Chief Tech/Sci/R&D Officer 2012-02-23
See the detail of Bill Lundberg's experience

Training of Bill Lundberg

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

64

1st degree connections

16

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies16

Health Technology

Health Technology

Health Technology

Antisoma Research Ltd.

Health Technology

Finance

Health Technology

Finance

Consumer Services

Health Technology

Health Services

Consumer Services

Consumer Services

Health Technology

Health Technology

Health Technology

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!